Nothing said here yet.
to join the conversation.
| Tousignant JenniferChief Legal Officer | Sell | 10,000 | $245.0K | Wed, Aug 19 |
| Tousignant JenniferChief Legal Officer | Sell | 4,212 | $103.2K | Wed, Aug 19 |
Viridian Therapeutics received FDA approval in June 2026 for Lumvoa, an IGF-1R antibody for active and chronic Thyroid Eye Disease, following Phase III data showing meaningful clinical benefits with a 12-week, 5-infusion IV regimen.
Viridian Therapeutics has seen a mixed share price story in recent years, which raises a straightforward question for anyone looking at the stock today. Is the current US$19.03 price tag adequately grounded in what the company is generating through its sales?
Viridian Therapeutics' (VRDN) Lumvoa is off to a "stronger start" than anticipated, RBC Capital Mark
Viridian Therapeutics (VRDN) is set to see "minimal" revenue growth in H2 before inflecting meaningf
WALTHAM, Mass., August 06, 2026--Viridian Therapeutics, Inc.
Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the 10 affordable biotech stocks to buy right now. On June 30, Goldman Sachs increased its target price for Viridian Therapeutics Inc.
Viridian Therapeutics (VRDN) has drawn fresh investor attention after recent trading left the stock at $19.08. Recent performance has been mixed across different periods, and the company’s business remains focused on therapies for serious and rare diseases.
Viridian Therapeutics stock has fallen 37.8% year to date, yet the valuation checks still point to the shares looking expensive rather than like a clear bargain.
With EPS growth for the next five years forecasted at 67.57%, Viridian Therapeutics, Inc. (NASDAQ:VRDN) is among the 12 Best Quality Stocks to Buy and Hold for the Next Decade.